文献速递乳腺癌放疗

患者与临床医生对导管原位癌放疗角色的看法

Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-01-09

基于SEER登记的女性DCIS患者调查显示,保乳术后23%省略放疗,洛杉矶县省略率是佐治亚州的两倍(31% vs 16%),最常见原因是医生建议不需放疗(62%)。临床医生中62%会讨论省略放疗,洛杉矶县医生更常讨论(67% vs 56%)。

要点

  • DCIS保乳术后23%患者省略放疗,地区差异显著(洛杉矶31% vs 佐治亚16%)。
  • 省略放疗主因是医生建议不需放疗(62%)和担心副作用(24%)。
  • 62%临床医生会讨论省略放疗,洛杉矶县医生更常讨论(67% vs 56%)。

核心结论

  • DCIS保乳术后省略放疗存在显著异质性,两地医生意见存在系统性差异。
  • 需要更精确的复发估计、专业组织指导和更好的沟通来提高治疗一致性。

研究设计与样本

  • 基于佐治亚州和洛杉矶县SEER登记的女性乳腺癌患者调查,保乳术后约2个月发送问卷,应答率70%,分析样本为538例单侧DCIS患者。
  • 同时调查两地治疗乳腺癌的761名外科医生和放射肿瘤科医生,539名应答(71%)。

主要发现

  • 保乳术后23%患者省略放疗,洛杉矶县省略率是佐治亚州的两倍(31% vs 16%;P < .001)。
  • 省略放疗最常见原因是医生建议不需放疗(62%)和担心副作用(24%),费用和交通未报告为影响因素。
  • 多因素调整后,低级别(OR 5.5,95%CI 2.5-12)和中级别(OR 3.2,95%CI 1.7-6.1)疾病及洛杉矶县SEER站点(OR 4.3,95%CI 2.3-8.2)与更高省略放疗显著相关。
  • 62%应答临床医生会为具有有利特征的DCIS患者讨论省略放疗,洛杉矶县医生比佐治亚州更常讨论(67% vs 56%;P = .01)。
  • 约三分之一临床医生会获取Oncotype DX DCIS评分。

关键数值与推荐

  • 保乳术后省略放疗率:总体23%,洛杉矶县31%,佐治亚州16%(P < .001)。
  • 低级别疾病OR 5.5(95%CI 2.5-12),中级别OR 3.2(95%CI 1.7-6.1),洛杉矶县站点OR 4.3(95%CI 2.3-8.2)与省略放疗相关。
  • 临床医生讨论省略放疗:总体62%,洛杉矶县67%,佐治亚州56%(P = .01)。

临床怎么用

  • 临床医生应了解DCIS保乳术后省略放疗存在地区差异,并与患者充分沟通。
  • 对于有利特征的DCIS,可考虑讨论省略放疗,但需结合复发风险和患者偏好。

局限性

  • 研究为调查设计,可能存在应答偏倚。
  • 仅纳入两个SEER登记区域,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate patient experiences with decisions regarding radiation therapy (RT) for ductal carcinoma in situ (DCIS), and to assess clinician views on the role of RT for DCIS with favorable features in the present era. METHODS AND MATERIALS: A sample of women with newly diagnosed breast cancer from the population-based Georgia and Los Angeles County Surveillance, Epidemiology, and End Results (SEER) registries were sent surveys approximately 2 months after undergoing breast-conserving surgery (BCS), with a 70% response rate. The analytic sample was limited to 538 respondents with unilateral DCIS. We also surveyed 761 surgeons and radiation oncologists treating breast cancer in those regions, of whom, 539 responded (71%). RESULTS: After BCS, 23% of patients omitted RT, with twice the rate of omission in Los Angeles County relative to Georgia (31% vs 16%; P < .001). The most common reasons for omitting RT were advice from a clinician that it was not needed (62%) and concern about side effects (24%). Cost and transportation were not reported as influential considerations. After covariate adjustment, low- and intermediate-grade disease (odds ratio [OR] 5.5, 95% confidence interval [CI] 2.5-12; and OR 3.2, 95% CI 1.7-6.1, respectively) and Los Angeles County SEER site (OR 4.3, 95% CI 2.3-8.2) were significantly associated with greater RT omission. Of the responding clinicians, 62% would discuss RT omission for a patient with DCIS with favorable features. Clinicians in Los Angeles County were more likely to discuss RT omission than were those in Georgia (67% vs 56%; P = .01). Approximately one third of clinicians would obtain the Oncotype DX DCIS score. CONCLUSIONS: The heterogeneity in RT omission after BCS for DCIS continues to be substantial, with systematic differences in provider opinions across the 2 regions we studied. Enhanced precision of recurrence estimates, guidance from professional organizations, and better communication are needed to improve the consistency of treatment in this controversial area.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Shumway DA, McLeod CM, Morrow M, et al. Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. Int J Radiat Oncol Biol Phys. 2018. PMID: 29439886. doi:10.1016/j.ijrobp.2018.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。